Autologous stem cell transplantation is here to stay for multiple myeloma (MM). However, once a treatment has been developed, there is no reason why it should not be improved. Here, Mohamad Mohty, MD, PhD, of University Pierre & Marie Curie, Paris, France, goes through some of the constant refinements that are being made to the drugs used to treat MM. Prof. Mohty discusses the debates these new improvements have sparked, and what he believes the most interesting drug innovations are, supported by findings by the staMINA trial (NCT01109004), before concluding his interview by giving a brief overview of maintenance therapy and some of the problems it still poses. This interview took place at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.
Refinements in MM treatment: a dynamic, ever-evolving field
